Dr Boris Shor Ph.D.
Dr. Shor has over 15-years of experience in basic and applied scientific research, including extensive background in both biologics and small molecule drug discovery across oncology and immunology.
He is currently a group leader at the Oncology Research Unit of Pfizer in New York. His team focuses on the discovery and early development of new antibody-drug conjugates (ADCs) and supports translational research efforts for the late stage assets. Dr. Shor also serves as a nonclinical pharmacology representative on the late stage clinical program, supporting BLA filings with worldwide regulatory authorities. In addition, Dr. Shor is routinely involved in accessing emerging sciences, R&D technology platforms and therapeutic products in US, Israel and Europe to ensure strategic integration of external opportunities in disease areas of interests to Pfizer.
From 2003 to 2008, he was a Senior Scientist at the department of Oncology Discovery at Wyeth Pharmaceuticals, where he made significant contribution to the understanding of biological action of Temsirolimus and of novel small molecule inhibitors of mTOR/PI3K pathway in cancers. During his time at Wyeth, Dr. Shor also led a drug discovery project and participated in biomarker identification efforts in support of mTOR kinase inhibitor program. Before joining Wyeth, Boris performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D.
He received an M.S. in Genetics from the St. Petersburg State University in 1995 and a Ph.D. in Molecular and Cell Biology at the SUNY Downstate Medical Center in 2001. In addition to his successful career in the pharmaceutical industry, Dr. Shor has established strong ties to the local biotech investment community in NYC. He provides mentorship and guidance to entrepreneurial academic researchers, biotech start-ups from US and abroad, and is a frequent guest speaker at industry panel discussions.